Finally, RUNX1/RUNX1T1-positive AML cell lines and patient cells are very sensitive toward the CDK4/6 inhibitor Palbociclib, exhibiting half-maximal responses at nanomolar concentrations. This evidence concerns the gene RUNX1 and acute myeloid leukemia.